相关实验视频

Updated: Jul 11, 2025

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

优化表达,净化,结构和功能评估的新型二维内蛋白 (GLP-1cpGLP-1)

Rawayh Muslim Albaghlany¹, Mohammad Bagher Shahsavani¹, Masaru Hoshino²

¹Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran.

|November 6, 2023

概括

研究人员通过结合人类胰岛素C-开发了一种新型的二维葡萄糖类-1 (GLP-1) 模拟物,GLP-1cpGLP-1,通过结合人类胰岛素C-. 这种GLP-1二元有效降低血糖,并刺激小鼠的胰岛素释放,显示出糖尿病的治疗潜力.

科学领域:

生物化学生物化学
分子生物学分子生物学
内分泌学在内分泌学.

背景情况:

类似葡萄糖-1 (GLP-1) 是一种关键的内激素,通过胰岛素分泌来调节食后葡萄糖水平.
目前的糖尿病疗法旨在增强GLP-1的作用或模仿其作用.

研究的目的:

设计和表征一种新的二维GLP-1模拟物,有可能提高治疗疗效.
评估设计的GLP-1类似物在降糖和胰岛素分泌中的体内疗效.

主要方法:

通过将人类的C-插入GLP-1二元体中,设计了一种二元GLP-1模拟物 (GLP-1cpGLP-1).
类似物被生产成一种与人类αB-晶体蛋白混合蛋白,并经过净化.
使用光谱方法,分析和动态光散射 (DLS) 评估了结构性质.
在体内对健康和糖尿病小鼠的研究评估了血糖降低和胰岛素释放.
使用尺寸排除HPLC分析了与人血清白蛋白的相互作用.

主要成果:

双面GLP-1模拟物 (GLP-1cpGLP-1) 已成功合成,净化到>99%的纯度,并被证明具有α-螺旋结构.
动态光散射表明了大型寡合结构的形成.
同类药物显著降低了血糖水平,并刺激了健康和糖尿病小鼠的胰岛素分泌.
与人血清白蛋白显著相互作用,表明血液循环时间延长.

结论:

新型二次GLP-1类似物GLP-1cpGLP-1表现出强大的降糖和胰岛素释放活性.
它与血清白蛋白的相互作用表明,在糖尿病管理中可能具有长期的治疗效果.
这种工程化隐形二次体代表了开发新型糖尿病治疗的有希望的进步.

关键词:

糖尿病糖尿病糖尿病葡萄糖耐受性测试 (GTT) 是一种测试方法.人类血清白蛋白 (HSA)新型的隐形素模仿治疗性类的治疗性类.

更多相关视频

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...